Zammarchi A, Pitscheider W, Mautone A, Oberhollenzer R, Lintner W, Erlicher A, Crepaz R, Osele L, Braito E
Divisione di Cardiologia, Ospedale Regionale Generale, Bolzano.
G Ital Cardiol. 1995 Aug;25(8):1011-9.
Nuclear cardiology permits the estimation of the myocardial infarction size and the result of the thrombolytic therapy. The aim of the study was to demonstrate the feasibility of the planar myocardial scintigraphy with Technetium-99-m-sestamibi in the coronary intensive care unit for the early identification of the infarct size and the result of the thrombolytic therapy.
We considered 10 patients affected by a first myocardial infarction (5 anterior and 5 inferior wall) then treated with thrombolytic therapy (APSAC 30 U. iv) within an interval of 3 hours from the onset of the symptoms. Technetium-99-m-sestamibi was injected before the thrombolytic therapy and the planar imaging was registered after 2-3 hours with a mobile gamma-camera. After 24 hours and before patient discharge we repeated the scintigraphic evaluation. Within 24 hours from the thrombolytic therapy the coronary angiography was performed for the demonstration of patency of the infarct-related artery. The left ventricle myocardial perfusion was divided in the 3 planar projections into 13 segments. The perfusion in each segment was evaluated with a perfusion score: 0 = normal perfusion, 1 = moderately reduced, 2 = severely reduced, 3 = absent. The sum of the hypoperfused segments represented the infarct size. A perfusion score improvement greater than 40% was considered a marker of reperfusion.
The infarct size involved 4.4 +/- 1.4 segments in the anterior and 2 +/- 0.6 segments in the inferior wall infarctions (p < 0.05). The scintigraphic imaging made 24 hours after the myocardial infarction allowed the diagnosis of coronary reperfusion in 7 patients. The coronary angiography demonstrated the infarct related artery patency in 9 patients (all with TIMI perfusion score = 3). The nuclear imaging at patient discharge provided the diagnosis or reperfusion in 8 cases and demonstrated an improvement of the myocardial perfusion score in 5 cases.
The scintigraphic imaging with Technetium-99-m-sestamibi in the patients with a myocardial infarction treated with thrombolytic therapy is feasible with a mobile gamma-camera in the intensive coronary care unit. The quality of planar imaging is good and allows the evaluation of myocardial infarct size and efficiency of thrombolytic therapy. An earlier scintigraphic imaging should be taken into consideration for a more timely non-invasive evaluation of patients who need coronary angiography and, if necessary, a rescue PTCA.
核心脏病学可用于估计心肌梗死面积及溶栓治疗效果。本研究旨在证明在冠心病重症监护病房使用锝-99m-甲氧基异丁基异腈进行平面心肌闪烁显像以早期识别梗死面积及溶栓治疗效果的可行性。
我们纳入了10例首次发生心肌梗死的患者(5例前壁梗死和5例下壁梗死),这些患者在症状发作后3小时内接受了溶栓治疗(静脉注射30 U茴香酰化纤溶酶原链激酶激活剂复合物)。在溶栓治疗前注射锝-99m-甲氧基异丁基异腈,并在2 - 3小时后用移动γ相机进行平面显像。在24小时后及患者出院前重复闪烁显像评估。在溶栓治疗后24小时内进行冠状动脉造影以显示梗死相关动脉的通畅情况。左心室心肌灌注在3个平面投影中分为13个节段。每个节段的灌注用灌注评分进行评估:0 = 正常灌注,1 = 中度减低,2 = 重度减低,3 = 无灌注。灌注减低节段的总和代表梗死面积。灌注评分改善大于40%被认为是再灌注的标志。
前壁梗死的梗死面积累及4.4±1.4个节段,下壁梗死累及2±0.6个节段(p < 0.05)。心肌梗死后24小时进行的闪烁显像使7例患者诊断为冠状动脉再灌注。冠状动脉造影显示9例患者梗死相关动脉通畅(所有患者心肌梗死溶栓试验灌注评分为3级)。患者出院时的核显像在8例中诊断为再灌注,5例显示心肌灌注评分改善。
对于接受溶栓治疗的心肌梗死患者,在冠心病重症监护病房使用移动γ相机进行锝-99m-甲氧基异丁基异腈闪烁显像是可行的。平面显像质量良好,可用于评估心肌梗死面积及溶栓治疗效果。对于需要冠状动脉造影及必要时进行急诊经皮冠状动脉腔内血管成形术的患者,应考虑更早进行闪烁显像以进行更及时的无创评估。